Integra Therapeutics


At Integra Therapeutics we are committed to create new gene writing tools that help to improve the scope, efficiency and safety of advanced therapies. Our purpose is to cure genetic and oncological diseases with high unmet medical need. Our leading technology platform solves the main limitations of gene therapy: size, precision, and stability. FiCAT combines the precision of CRISPR-Cas and the transfer efficiency of an engineered piggybac transposase protein with capability to deliver small and large payloads.